Marie Phelan first learned about MDMA through a flyer for veterans with PTSD. She had no idea that this psychoactive drug, often called ecstasy or molly, would change her life. “MDMA cracked my heart wide open,” she says. For Phelan, who served in the U.S. Army and was deployed to Iraq, the therapy felt like dropping a heavy backpack, taking out burdens one by one, and letting them float away.
She’s not alone. Many are turning to psychedelics for trauma relief. Phelan is part of a small but growing group of Americans involved in clinical trials that explore the benefits of psychedelic-assisted therapy. Recently, access to these therapies is becoming more mainstream, ushering in new options for patients and sparking interest in the medical community.
In April 2026, President Trump signed an executive order aimed at speeding up research on psychedelic drugs for mental health. This shift from past stances—like his earlier emphasis on strict cannabis policies—highlights a new recognition of these substances’ potential. The White House stated that psychedelics may help patients who haven’t found relief from traditional therapies.
This executive order prompted investors to flock to the sector, driving up stocks for companies like Compass Pathways, Usona Institute, and Transcend Therapeutics, which are working on psychedelic treatments. Some analysts believe this could legitimize an industry often viewed as fringe.
Psychedelics like psilocybin (found in magic mushrooms) and MDMA have been studied for conditions like depression and PTSD. But the science is still debated. Dr. Brandon Weiss from Johns Hopkins points out that each psychedelic has different safety profiles and risks. For instance, while MDMA is classified as an empathogen, it is often grouped with psychedelics due to its therapeutic use.
Research shows promise. In late-stage trials, 71% of participants with severe PTSD no longer met the criteria for the disorder after undergoing MDMA-assisted therapy. However, the FDA previously rejected an application for this therapy, citing the need for more data. This illustrates how cautious regulators remain.
Globally, other countries are moving ahead. Australia became the first to permit authorized psychiatrists to prescribe MDMA and psilocybin for specific mental health issues in 2023. Canada and Switzerland are also expanding their studies into these therapies, reflecting a growing global movement toward alternative mental health treatments.
However, risks remain. Patients undergoing these therapies can experience intense emotions or distress. In some trials, doctors have to use additional medications to help calm patients. Phelan describes her time with MDMA therapy as a controlled setting where she confronted years of trauma, contrasting it with typical pill prescriptions.
Veteran advocates like Juliana Mercer see the executive order as recognition of the need for alternative treatments. Mercer, who found healing through psychedelic therapy, believes it provides essential permission to begin the healing process.
The current climate also raises questions about why the timing of the executive order matters. Critics argue it’s a strategic move by Trump to regain support from veterans as elections approach. However, many, like Phelan, doubt this will significantly sway public opinion.
While the political landscape shifts, the science and safety of psychedelic treatments must remain at the forefront. As Weiss cautions, rushing the approval process could undermine the careful research that’s needed to ensure these therapies are not only effective but safe.
As this field evolves, understanding the complexities of psychedelic therapy becomes vital. For those exploring these options, the relationship between mental health and psychedelics is not just about trends—it’s about real changes in lives.
For further insights, check the Multidisciplinary Association for Psychedelic Studies, which advocates for the responsible development of psychedelic therapies.
Source link
Health care industry,Breaking News: Politics,Politics,Donald Trump,Iraq,Compass Pathways PLC,United States,United Kingdom,business news
